ChemT Biotechnology
AI-driven biotech founded in October 2024 across Singapore and the United States, building the CelMo virtual-cell platform as an intelligence layer for biomanufacturing and CMC; it simulates how cells respond to manufacturing conditions and genetic changes, using AI-designed small molecules to steer cell behaviour and improve production processes.
Headquarters
Singapore / United States
Year Founded
2024
Founders
Jie Sun (co-founder and CEO), Ling Wu (co-founder and President)
Country
Singapore
Financial Information
Funding Stage
Seed
Recent Funding
$5M
Funding By
Wavemaker Ventures, SEEDS, Wavemaker 360 Health, Draper University Ventures, Temasek Life Sciences Accelerator
Core Technology
CelMo virtual-cell platform (AI-designed small molecules plus proprietary biological data and wet-lab validation)
Product Type
AI Platform
Pipeline Stage (Very Important)
Regulatory Status
- IND Filed: N/A
- FDA/EMA Status: N/A
- Clinical Trial Registration: N/A
- Patents / IP Status: Not disclosed
Partnerships
Pharma Collaborations
40+ commercial partnerships across biomanufacturing (undisclosed)
Academic / Hospital Tie-ups
Not disclosed
CRO/CDMO Partnerships
None disclosed
Market & Differentiation
An AI intelligence layer aimed at CMC and biomanufacturing processes rather than drug discovery alone